202 related articles for article (PubMed ID: 35236082)
1. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
2. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
3. What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Baboudjian M; Roubaud G; Fromont G; Gauthé M; Beauval JB; Barret E; Brureau L; Créhange G; Dariane C; Fiard G; Mathieu R; Ruffion A; Rouprêt M; Renard-Penna R; Sargos P; Ploussard G;
World J Urol; 2023 Aug; 41(8):2033-2041. PubMed ID: 36484817
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
5. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer.
Ranasinghe W; Chapin BF; Kim IY; Sooriakumaran P; Lawrentschuk N
BJU Int; 2020 Jun; 125(6):792-800. PubMed ID: 32176456
[TBL] [Abstract][Full Text] [Related]
6. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
7. Role of radical prostatectomy in metastatic prostate cancer: A review.
Metcalfe MJ; Smaldone MC; Lin DW; Aparicio AM; Chapin BF
Urol Oncol; 2017 Apr; 35(4):125-134. PubMed ID: 28190749
[TBL] [Abstract][Full Text] [Related]
8. Role of surgery in oligometastatic prostate cancer.
Jenjitranant P; Touijer KA
Prostate Int; 2019 Dec; 7(4):125-130. PubMed ID: 31970136
[TBL] [Abstract][Full Text] [Related]
9. Radical cytoreductive prostatectomy in men with prostate cancer and oligometastatic disease.
Heidenreich A; Pfister D
Curr Opin Urol; 2020 Jan; 30(1):90-97. PubMed ID: 31724996
[TBL] [Abstract][Full Text] [Related]
10. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer.
Pellegrino A; Gandaglia G; de Angelis M; Fallara G; Mazzone E; Stabile A; Pellegrino F; Robesti D; Leni R; Scuderi S; Cucchiara V; Cirulli GO; Barletta F; Montorsi F; Briganti A
World J Urol; 2023 Aug; 41(8):2069-2076. PubMed ID: 37326656
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review.
Becker JA; Berg KD; Røder MA; Brasso K; Iversen P
Scand J Urol; 2018 Feb; 52(1):1-7. PubMed ID: 28818014
[TBL] [Abstract][Full Text] [Related]
12. Emerging role for local therapy in oligometastatic prostate cancer.
Khondakar NR; Owens-Walton J; Daneshvar M; Williams C; O'Connor L; Yerram NK; Pinto PA
Clin Adv Hematol Oncol; 2021 Jul; 19(7):460-467. PubMed ID: 34236345
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study.
Heidenreich A; Pfister D; Porres D
J Urol; 2015 Mar; 193(3):832-8. PubMed ID: 25254935
[TBL] [Abstract][Full Text] [Related]
14. Emerging role of cytoreductive prostatectomy in patients with metastatic disease.
Jaber Y; Reichard CA; Chapin BF
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S505-S513. PubMed ID: 30363448
[TBL] [Abstract][Full Text] [Related]
15. [Cytoreductive radical prostatectomy for prostate cancer with minimal osseous metastases: results of a first feasibility and case control study].
Heidenreich A; Pfister D; Brehmer B; Porres D
Urologe A; 2015 Jan; 54(1):14-21. PubMed ID: 25519996
[TBL] [Abstract][Full Text] [Related]
16. Current evidence on local therapy in oligometastatic prostate cancer.
Basourakos SP; Henning G; Karnes RJ
Curr Opin Urol; 2024 May; 34(3):198-203. PubMed ID: 38305293
[TBL] [Abstract][Full Text] [Related]
17. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
18. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract][Full Text] [Related]
19. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis.
Wang Y; Qin Z; Wang Y; Chen C; Wang Y; Meng X; Song N
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29263146
[TBL] [Abstract][Full Text] [Related]
20. [Radiotherapy for local disease in metastatic prostate cancer.].
Cambeiro M; Calvo FA
Arch Esp Urol; 2018 Mar; 71(3):298-305. PubMed ID: 29633951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]